Videos

The associate professor from UC San Diego discussed promising efficacy and safety data from a phase 1/2 trial.

Geoffrey Hodge, chief executive officer of SOTIO Biotech US, discussed the company's development of the BOXR cell therapy platform.

The chief scientific officer and senior vice president of the Parkinson’s Foundation discussed mutations the Parkinson’s Foundation has identified.

Susan Ruediger, founder and chief mission officer, CMT Research Foundation, discussed the foundation’s mission.

The chief program officer of the Alliance for Cancer Gene Therapy discussed the work the nonprofit is doing.

The associate director of Research at Senti Biosciences discussed the company's research on using logic-gated CAR-NK cells for the treatment of AML and solid tumors.

The chief scientific officer at TScan Therapeutics discussed the company’s SafetyScan technology.

The co-founder and executive chairman of TC BioPharm discussed his thoughts on the regulatory, logistical, and quality hurdles of manufacturing cell therapies.

The senior director and clinical program leader, Translational Clinical Oncology at Novartis Institutes for BioMedical Research, discussed new data from the phase 1 study.

The research fellow from Harvard Medical School discussed blocking IFNg as a potential approach to reduce toxicities.

The instructor of Medicine, Division of Hematology and Oncology, Hospital of the University of Pennsylvania discussed his thoughts on the potential of targeting mutant KRAS with immunotherapy.

MUSC recently launched In Your DNA SC, a 4-year study to collect and glean insights from genetic testing in the general population.

The global head of research and development at Atara Biotherapeutics discussed ATA188 ahead of anticipated data readouts this month.

The associate professor at Fred Hutch Cancer Center discussed data presented at the EHA 2022 Congress.

The chief of cancer immunotherapy at Rutgers Cancer Institute discussed clinical results with different cell therapy approaches.

The scientist at A2 Biotherapeutics discussed the company’s dual-receptor Tmod technology.

The acting chief of the oncology branch of the Center for Biologics Evaluation and Research at the FDA discussed the evolution of cell therapies in the past decade.

Susan Ruediger, founder and chief mission officer, CMT Research Foundation, discussed the panel discussion she participated in at BIO 2022.

Michael Parini, chief executive officer and director, Freeline Therapeutics, discussed the company’s pipeline and mission.

The senior vice president of clinical development at Passage Bio discussed intracisternal magna administration of PBGM01.

The chief of the lymphoma division and oncologist at Levine Cancer Institute discussed data from real-world experience studies.

The director of the Pediatric Hemophilia and Coagulation Disorders Program at CS Mott Children’s Hospital discussed common challenges with gene therapy clinical trials.

The clinical professor of medicine, Helen Diller Family Comprehensive Cancer Center, UCSF, discussed cilta-cel and upcoming cell therapies.

The director of the Alleghany Health Network Institute of Cellular Therapeutics discussed possible applications of the procedure.

The chief scientific officer of the CMT Research Foundation discussed investigative cell and gene therapy approaches for treating CMT.

Oncologist discuss the possibility of earlier-line CAR T-cell therapies in MM.

The director of the Center for Multiple Myeloma at Mass Gen discussed current CAR T-cell therapies in multiple myeloma.

Jan ter Meulen, MD, PhD, chief scientific officer, Obsidian Therapeutics, discussed the potential of the cytoDRIVE platform.